In its latest effort to attack high drug costs, the Trump administration wants to allow privately run Medicare Advantage plans to require patients to pursue step therapy, which means anyone who needs a costly, physician-administered drug must first try a cheaper medicine to see if it works.

With about 19 million beneficiaries covered by these plans, the move is projected to save 15 percent to 20 percent of the $11.9 billion spent on Part B drugs, which are infused or injected medicines. Some of these are pricey specialty drugs for hard-to-treat diseases and ailments.

Unlock this article by subscribing to STAT Plus. Try it FREE for 30 days!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy